Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
After some six years at the post, Amgen’s finance chief is telegraphing his exit from the California pharma by early next year. | After some six years at the post, Amgen’s finance chief is telegraphing his exit from the California pharma by early next year.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise

Peter Griffith will be the second high-profile exec to leave Amgen this year when he retires on Sept. 1. Thomas Dittrich will…

Last week’s unexpected CEO shuffle at for-profit health system Ardent Health was a “proactive, not reactive” move as the…

In the wake of a recent safety scare in a confirmatory trial of its antibody-drug conjugate Zynlonta, ADC Therapeutics is…

Two Big Pharmas are shrinking their U.S. | AbbVie's 85 layoffs are tied to its Allergan Aesthetics headquarters in California,…

Bristol Myers Squibb and Hengrui Pharma signed a massive deal worth up to $15.2 billion. Takeda aims to cut 4,500 jobs in fiscal…

As AbbVie continues to capitalize on its deal for ImmunoGen with the growth of commercial antibody-drug conjugate (ADC) Elahere,…